Trial Profile
A Phase 1 Evaluation of the Safety and Tolerability of Niraparib in Combination With Everolimus in Advanced Gynecologic Malignancies and Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Niraparib (Primary)
- Indications Advanced breast cancer; Cervical cancer; Endometrial cancer; Ovarian cancer
- Focus Adverse reactions
- 24 Aug 2021 Planned End Date changed from 1 Jun 2022 to 1 Jun 2024.
- 24 Aug 2021 Planned primary completion date changed from 1 Jul 2021 to 1 Jun 2023.
- 24 Aug 2021 Status changed from recruiting to active, no longer recruiting.